695213-59-3 Usage
Description
N-benzyl-1-pentyl-1H-indole-3-carboxamide is a synthetic chemical compound with the molecular formula C20H24N2O. It belongs to the class of indole-3-carboxamide compounds and is commonly used in research settings as a potential agonist for the cannabinoid receptor CB2. This chemical has been studied for its potential pharmacological properties, including its interaction with the endocannabinoid system and its possible role in the treatment of conditions such as inflammation, pain, and neurological disorders. Research on N-benzyl-1-pentyl-1H-indole-3-carboxamide continues to explore its potential therapeutic applications and biological effects.
Uses
Used in Pharmaceutical Research:
N-benzyl-1-pentyl-1H-indole-3-carboxamide is used as a research compound for investigating its potential as a CB2 receptor agonist. Its interaction with the endocannabinoid system is of interest for the development of new therapeutic agents.
Used in Inflammation Treatment:
N-benzyl-1-pentyl-1H-indole-3-carboxamide is used as a potential anti-inflammatory agent, as its agonistic activity on the CB2 receptor may help modulate inflammatory responses and alleviate symptoms associated with inflammatory conditions.
Used in Pain Management:
N-benzyl-1-pentyl-1H-indole-3-carboxamide is used as a candidate for pain relief, leveraging its interaction with the endocannabinoid system to potentially reduce pain perception and manage chronic pain conditions.
Used in Neurological Disorders Research:
N-benzyl-1-pentyl-1H-indole-3-carboxamide is used as a research tool to explore its potential in treating neurological disorders, given the involvement of the endocannabinoid system in various neurological processes and the compound's ability to modulate receptor activity.
Note: The uses listed are based on the potential applications derived from the compound's interaction with the endocannabinoid system and its status as a research compound. Actual clinical applications may vary and are subject to ongoing research and regulatory approval.
Check Digit Verification of cas no
The CAS Registry Mumber 695213-59-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,5,2,1 and 3 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 695213-59:
(8*6)+(7*9)+(6*5)+(5*2)+(4*1)+(3*3)+(2*5)+(1*9)=183
183 % 10 = 3
So 695213-59-3 is a valid CAS Registry Number.
695213-59-3Relevant articles and documents
Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA
Ametovski, Adam,Macdonald, Christa,Manning, Jamie J.,Haneef, S. A. Syed,Santiago, Marina,Martin, Lewis,Sparkes, Eric,Reckers, Andrew,Gerona, Roy R.,Connor, Mark,Glass, Michelle,Banister, Samuel D.
, p. 3672 - 3682 (2020/11/18)
Synthetic cannabinoid receptor agonists (SCRAs) represent the most rapidly expanding class of new psychoactive substances (NPSs). Despite the prevalence and potency of recent chiral indole-3-carboxamide SCRAs, few pharmacological data are available regarding the enantiomeric bias of these NPSs toward human CB1 and CB2 receptors. A series of homochiral indole-3-carboxamides derived from (S)- and (R)-α-methylbenzylamine and featuring variation of the 1-alkyl substituent were prepared, pharmacologically evaluated, and compared to related achiral congeners derived from cumyl- and benzylamine. Competitive binding assays demonstrated that all analogues derived from either enantiomer of α-methylbenzylamine (14-17) showed affinities for CB1 (Ki = 47.9-813 nM) and CB2 (Ki = 47.9-347 nM) that were intermediate to that of the corresponding benzylic (10-13, CB1 Ki = 550 nM to >10 μM; CB2 Ki = 61.7 nM to >10 μM) and cumyl derivatives (6-9, CB1 Ki = 12.6-21.4 nM; CB2 Ki = 2.95-24.5 nM). In a fluorometric membrane potential assay, all α-methylbenzyl analogues (excluding 17) were potent, efficacious agonists of CB1 (EC50 = 32-464 nM; Emax = 89-104%) and low efficacy agonists of CB2 (EC50 = 54-500 nM; Emax = 52-77%), with comparable or greater potency than the benzyl analogues and much lower potency than the cumyl derivatives, consistent with binding trends. The relatively greater affinity and potency of (S)-14-17 compared to (R)-14-17 analogues at CB1 highlighted an enantiomeric bias for this series of SCRAs. Molecular dynamics simulations provided a conformational basis for the observed differences in agonist potency at CB1 pending benzylic substitution.
